Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance

Triplet combinations containing a proteasome inhibitor are a standard of care in newly diagnosed multiple myeloma (NDMM). We examined the long-term efficacy and safety of the all-oral combination of weekly ixazomib plus lenalidomide-dexamethasone (IRd), followed by single-agent ixazomib maintenance...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Shaji Kumar, Jesús G. Berdeja, Rubén Niesvizky, Sagar Lonial, Jacob P. Laubach, Mehdi Hamadani, A. Keith Stewart, Parameswaran Hari, Vivek Roy, Robert Vescio, Jonathan L. Kaufman, Deborah Berg, Eileen Liao, S. Vincent Rajkumar, Paul G. Richardson
Materialtyp: Artigo
Språk:engelska
Publicerad: 2019
Länkar:https://doi.org/10.1038/s41375-019-0384-1
https://www.nature.com/articles/s41375-019-0384-1.pdf
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Internet

https://doi.org/10.1038/s41375-019-0384-1
https://www.nature.com/articles/s41375-019-0384-1.pdf

Liknande verk